Zacks Research Issues Optimistic Outlook for PAHC Earnings

Phibro Animal Health Corporation (NASDAQ:PAHC) – Analysts at Zacks Research raised their Q1 2027 EPS estimates for shares of Phibro Animal Health in a research note issued to investors on Monday, January 5th. Zacks Research analyst Team now anticipates that the company will earn $0.73 per share for the quarter, up from their prior forecast of $0.72. Zacks Research has a “Strong-Buy” rating on the stock. The consensus estimate for Phibro Animal Health’s current full-year earnings is $1.95 per share. Zacks Research also issued estimates for Phibro Animal Health’s Q4 2027 earnings at $0.69 EPS, FY2027 earnings at $2.76 EPS and FY2028 earnings at $3.03 EPS.

Phibro Animal Health (NASDAQ:PAHC) last released its quarterly earnings results on Wednesday, November 5th. The company reported $0.73 EPS for the quarter, topping the consensus estimate of $0.58 by $0.15. The business had revenue of $363.89 million for the quarter, compared to analysts’ expectations of $345.44 million. Phibro Animal Health had a return on equity of 36.26% and a net margin of 4.85%.Phibro Animal Health has set its FY 2026 guidance at 2.640-2.810 EPS.

A number of other analysts also recently weighed in on PAHC. JPMorgan Chase & Co. raised their price target on shares of Phibro Animal Health from $45.00 to $50.00 and gave the stock an “overweight” rating in a research report on Friday, November 7th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Phibro Animal Health in a report on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, three have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat, Phibro Animal Health presently has an average rating of “Hold” and a consensus price target of $31.40.

Phibro Animal Health Price Performance

PAHC stock opened at $39.72 on Thursday. The stock’s 50 day moving average is $40.89 and its two-hundred day moving average is $36.40. Phibro Animal Health has a 52-week low of $16.16 and a 52-week high of $46.42. The company has a market capitalization of $1.61 billion, a PE ratio of 23.93, a P/E/G ratio of 1.12 and a beta of 0.79. The company has a quick ratio of 1.35, a current ratio of 3.09 and a debt-to-equity ratio of 2.32.

Phibro Animal Health Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, December 17th. Shareholders of record on Wednesday, November 26th were issued a $0.12 dividend. This represents a $0.48 dividend on an annualized basis and a yield of 1.2%. The ex-dividend date of this dividend was Wednesday, November 26th. Phibro Animal Health’s payout ratio is currently 28.92%.

Insiders Place Their Bets

In other news, CEO Jack Bendheim sold 5,752 shares of the firm’s stock in a transaction dated Thursday, December 11th. The shares were sold at an average price of $40.93, for a total value of $235,429.36. Following the transaction, the chief executive officer directly owned 39,200 shares in the company, valued at approximately $1,604,456. This trade represents a 12.80% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders have sold a total of 146,882 shares of company stock worth $6,351,593 in the last three months. 50.13% of the stock is owned by insiders.

Hedge Funds Weigh In On Phibro Animal Health

Hedge funds and other institutional investors have recently modified their holdings of the company. Hughes Financial Services LLC bought a new stake in Phibro Animal Health in the 3rd quarter valued at about $40,000. Financial Management Professionals Inc. acquired a new stake in shares of Phibro Animal Health in the second quarter valued at approximately $32,000. iSAM Funds UK Ltd bought a new stake in shares of Phibro Animal Health during the third quarter valued at approximately $61,000. Advisory Services Network LLC bought a new stake in shares of Phibro Animal Health during the third quarter valued at approximately $96,000. Finally, EverSource Wealth Advisors LLC boosted its position in shares of Phibro Animal Health by 7,671.4% during the second quarter. EverSource Wealth Advisors LLC now owns 2,720 shares of the company’s stock worth $69,000 after buying an additional 2,685 shares during the period. Institutional investors and hedge funds own 99.34% of the company’s stock.

About Phibro Animal Health

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.